scholarly journals Symptoms associated with Lewy body disease in mild cognitive impairment

2017 ◽  
Vol 32 (11) ◽  
pp. 1163-1171 ◽  
Author(s):  
Paul C. Donaghy ◽  
Nicola Barnett ◽  
Kirsty Olsen ◽  
John-Paul Taylor ◽  
Ian G. McKeith ◽  
...  
2020 ◽  
Vol 10 (8) ◽  
pp. 540
Author(s):  
Lauren Revie ◽  
Calum A Hamilton ◽  
Joanna Ciafone ◽  
Paul C Donaghy ◽  
Alan Thomas ◽  
...  

Background: Visual hallucinations (VH) are a common symptom in dementia with Lewy bodies (DLB); however, their cognitive underpinnings remain unclear. Hallucinations have been related to cognitive slowing in DLB and may arise due to impaired sensory input, dysregulation in top-down influences over perception, or an imbalance between the two, resulting in false visual inferences. Methods: Here we employed a drift diffusion model yielding estimates of perceptual encoding time, decision threshold, and drift rate of evidence accumulation to (i) investigate the nature of DLB-related slowing of responses and (ii) their relationship to visuospatial performance and visual hallucinations. The EZ drift diffusion model was fitted to mean reaction time (RT), accuracy and RT variance from two-choice reaction time (CRT) tasks and data were compared between groups of mild cognitive impairment (MCI-LB) LB patients (n = 49) and healthy older adults (n = 25). Results: No difference was detected in drift rate between patients and controls, but MCI-LB patients showed slower non-decision times and boundary separation values than control participants. Furthermore, non-decision time was negatively correlated with visuospatial performance in MCI-LB, and score on visual hallucinations inventory. However, only boundary separation was related to clinical incidence of visual hallucinations. Conclusions: These results suggest that a primary impairment in perceptual encoding may contribute to the visuospatial performance, however a more cautious response strategy may be related to visual hallucinations in Lewy body disease. Interestingly, MCI-LB patients showed no impairment in information processing ability, suggesting that, when perceptual encoding was successful, patients were able to normally process information, potentially explaining the variability of hallucination incidence.


2019 ◽  
Vol 34 (8) ◽  
pp. 1244-1250 ◽  
Author(s):  
Eleanor King ◽  
John O'Brien ◽  
Paul Donaghy ◽  
Caroline H. Williams-Gray ◽  
Rachael A. Lawson ◽  
...  

2019 ◽  
Vol 405 ◽  
pp. 20
Author(s):  
B. Boeve ◽  
T. Ferman ◽  
N. Graff-Radford ◽  
D. Knopman ◽  
J. Graff-Radford ◽  
...  

Brain ◽  
2009 ◽  
Vol 133 (2) ◽  
pp. 540-556 ◽  
Author(s):  
Jennifer Molano ◽  
Bradley Boeve ◽  
Tanis Ferman ◽  
Glenn Smith ◽  
Joseph Parisi ◽  
...  

2019 ◽  
Vol 15 ◽  
pp. P1235-P1235
Author(s):  
Bradley F. Boeve ◽  
Tanis J. Ferman ◽  
Neill R. Graff-Radford ◽  
David S. Knopman ◽  
Jonathan Graff-Radford ◽  
...  

2020 ◽  
Vol 35 (10) ◽  
pp. 1250-1259
Author(s):  
Alan J. Thomas ◽  
Calum A. Hamilton ◽  
Paul C. Donaghy ◽  
Carmen Martin‐Ruiz ◽  
Chris M. Morris ◽  
...  

2008 ◽  
Vol 67 ◽  
pp. 15
Author(s):  
Chloé de Boysson ◽  
Sylvie Belleville ◽  
Diane Goupil ◽  
Céline Souchay ◽  
Natalie Phillips ◽  
...  

2021 ◽  
Vol 14 ◽  
pp. 175628642110576
Author(s):  
Melissa J. Armstrong

Dementia with Lewy bodies (DLB) is a clinical diagnosis representing a specific presentation of a pathological α-synucleinopathy (Lewy body disease). DLB is one entity under the broader term Lewy body dementia, which also includes Parkinson’s disease dementia. Recent advances in DLB include publication of updated diagnostic criteria and recognition of prodromal DLB states, including mild cognitive impairment, delirium-onset, and psychiatric-onset forms. Research criteria for the mild cognitive impairment form of DLB were published in 2020. Increasing research shows that concomitant Alzheimer’s disease pathology in individuals with DLB is common in addition to the α-synucleinopathy pathology. This has implications for biomarker use and expected progression. Identifying biomarkers for DLB is an area of active research. Cerebrospinal fluid and skin biopsy tests are now commercially available in the United States, but their role in routine clinical care is not yet established. Additional research and biomarkers are needed. Research suggests that median survival after DLB diagnosis is 3–4 years, but there are rapidly and slowly progressive forms. Most individuals with DLB die of complications of the disease. Clinical trials for individuals with DLB have increased over the last 5 years, targeting both symptoms and underlying pathology. Effective therapies remain an unmet need, however. This review focuses on recent advances with an emphasis on literature that informs clinical care.


Sign in / Sign up

Export Citation Format

Share Document